Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2011-05-10
2011-05-10
Hui, San-ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S174000, C514S734000
Reexamination Certificate
active
07939514
ABSTRACT:
Topical application of a triple combination immixture of fluocinolone acetonide, tretinoin and hydroquinone is useful for the maintenance therapy of melasma to prevent hyperpigmentation recurrence or reduce the severity of the hyperpigmentation recurrence.
REFERENCES:
patent: 2004/0037201 (2004-02-01), Sako et al.
Torok, American Journal of Clinical Dermatology, Jul. 2006;7(4):223-230.
Taylor et al., “Efficacy and Safety of a New Triple-Combination Agent for the Treatment of Facial Melasma,”Cutis, Therapeutics for the Clinician, vol. 72, pp. 67-72, Jul. 2003, New Jersey.
Cook-Bolden, et al., “The Use of a Triple-Drug Combination Product and Procedures for the Treatment of Hyperpigmentary Disorders,”Cosmetic Dermatology, vol. 18, No. 8, pp. 589-594, 2005, Knolls Pub. Group, New Jersey.
Cestari et al., Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy,British Journal of Dermatology, 2006 156 (suppl. 1), 13-20, British Association of Dermatologists, Britain.
Torok et al., “A Large 12-month Extension Study of an 8-week trial to Evaluate the Safety and Efficacy of Triple Combination (TC) Cream in Melasma Patients Previously Treated with TC Cream or One of Its Dyads,”Journal of Drugs in Dermatology, Sep./Oct. 2005, vol. 4, Issue 5, pp. 592-597, New York.
Grimes et al., “Community-Based Trial of a Triple-Combination Agent for the Treatment of Facial Melasma,”Cutis, Therapeutics for the Clinician, vol. 77, No. 3, Mar. 2006, pp. 177-184, New Jersey.
Guevara et al., Melasma treated with hydroquinone, tretinoin, and a fluorinated steroid,International Journal of Dermatology, 2001, vol. 40, No. 3, 210-215, Blackwell Science Ltd., US.
Katz et al., “Intermittant Corticosteroid Maintenance Treatment of Psoriasis: A Double-Blind Multicenter Trial of Augmented Betamethasone Dipropionate Ointment in a Pulse Dose Treatment Regimen,”Dermatologica1991:183:269-274, Karget AG, Basel.
International Search Report for corresponding PCT/EP/2007/064271, issued Mar. 27, 2008 in English.
International Preliminary Report on Patentability for corresponding PCT/EP2007/064271, issued Jun. 24, 2009, 9 pages in English.
Buchanan Ingersoll & Rooney P.C.
Galderma S.A.
Hui San-ming
LandOfFree
Administration of fluocinolone acetonide, tretinoin and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Administration of fluocinolone acetonide, tretinoin and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administration of fluocinolone acetonide, tretinoin and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2619816